Table 3.
Association between triptan exposure and vascular events at 90 days (Cohort study, Cox model)
| Hazard ratio (95%CI) | Adjusted hazard ratio (95% CI) Exposed-unexposed |
Adjusted hazard ratio (95% CI) Cumulative dose |
Adjusted hazard ratio (95% CI) Time-varying |
|
|---|---|---|---|---|
| Exposure to triptans | ||||
| Controls (non-exposed) | 1 | 1 | ||
| Exposure to triptans (Triptan group) | 1.243 (1.043–1.483) | 1.252 (1.050–1.494) | ||
| Exposure to triptans (time-varying) | ||||
| Currently exposed at the time of event | 8.691 (5.186–14.564) | - | - | 8.745 (5.214–14.668) |
| Not currently exposed at the time of event | 0.930 (0.760–1.137) | 0.926 (0.757–1.133 | ||
| Cumulative dose (triptans) since index date (DDDs) | ||||
| Controls (non-exposed) | 1 | - | 1 | - |
| < 12 | 1.861 (1.431–2.420) | 1.852 (1.424–2.410) | ||
| 12 | 1.172 (0.876–1.566) | 1.173 (0.877–1.569) | ||
| > 12 | 0.600 (0.383–0.940) | 0.598 (0.382–0.937) | ||
| Charlson’s score (0) | 1 | |||
| 1–2 | 0.949 (0.644–1.399) | - | - | - |
| 3–4 | 1.152 (0.674–1.967) | |||
| > 5 | 1.337 (0.646–2.767) | |||
| Days of hospitalization (0) | 1 | - | ||
| ≤ 4 | 0.861 (0.539–1.375) | - | ||
| > 5 | 0.852 (0.537–1.351) | |||
| Number of medical visits (0–2) | 1 | - | - | - |
| 3–4 | 1.154 (0.667–1.996) | |||
| 5–7 | 0.907 (0.537–1.531) | |||
| > 7 | 1.223 (0.759–1.971) | |||